Acknowledgements 

Professor Finn Boerlum Kristensen, PhD, MD, Danish Centre for Health Economics, University of Southern Denmark, Denmark 

Professor, Laura Pizzi, PhD, Rutgers University, Ernest Mario School of Pharmacy, NJ, USA  

Karen Worley, MS, PhD, Director, Humana Healthcare, OH, USA 

Bruce Gingles, Cook Medical, IN, USA 

James F Murray, PhD, Research Fellow, Eli Lilly and Company, IN, USA 

Carla Zema, PhD, Zema Consulting, AL, USA  

Authors & Contributors 


Authors:  

Patrick LaFontaine, Associate Director, Global HEOR, Oncology, Sanofi, NJ, USA 

Daryl S. Spinner, PhD MBA, BS, VP, Market Access & Reimbursement, Variantyx, Inc., NC, USA 

Contributors:  

Kelly Lenahan, MPH, Research Associate II, Center for the Evaluation of Value and Risk in Health (CEVR), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, MA, USA 

John Guerino, MHS, Manager, Scientific and Health Policy Initiatives, ISPOR  

Theresa Tesoro, MSN, Associate Director, Scientific and Health Policy Initiatives, ISPOR 

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×